华创医药周观点：海外CXO 2025财报总结&2026年展望 2026/02/28

Core Viewpoint - The report highlights the strong growth potential of the Chinese pharmaceutical industry, particularly in innovative drugs, with a significant increase in the number of therapies under development and a growing share in the global market [10]. Market Overview - The CITIC pharmaceutical index rose by 0.41% this week, underperforming the CSI 300 index by 0.67 percentage points, ranking 24th among 30 primary industries [9]. - The top ten stocks by growth this week included Aidi Te, Koyuan Pharmaceutical, and Duorui Pharmaceutical, while the bottom ten included Zexing Pharmaceutical and Meihua Medical [9]. Investment Themes - Innovative Drugs: China has become a key player in global innovative drug development, with the total overseas licensing amount for domestic new drugs exceeding $10 billion for the first time in 2021, indicating a sustained increase in overseas licensing activity [10]. - Traditional Chinese Medicine: The market for essential medicines is expected to see significant growth, particularly for unique essential medicines, as the new medical insurance catalog expands [12]. - Medical Devices: The pressure from centralized procurement for high-value consumables is easing, and the industry is expected to see continued development driven by innovation [13]. - Pharmaceutical Supply Chain (CXO + APIs): The domestic CXO companies are experiencing good growth in front-end orders, which is expected to translate into performance improvements [13]. - Life Sciences Services: The industry is seeing a recovery in demand, with a positive outlook for revenue growth starting from Q4 2024 [13]. Company Performance and Projections - Medpace: The company reported a revenue growth of 20% and has a clear revenue and profit growth guidance for 2026, with expected revenue growth of 4.7-6.0% [15][88]. - IQVIA: The company is benefiting from an improved macro environment, with a projected total revenue of $171.5-173.5 billion for 2026 [55]. - Lonza: The company expects a revenue growth of 11-12% for 2026, driven by strong demand for outsourcing and maturing growth projects [34][38]. - Samsung Biologics: The company anticipates a revenue growth of 15-20% for 2026, with strong performance in its biologics segment [34][46]. Financial Highlights - IQVIA: Reported Q4 2025 revenue of $4.364 billion, a year-on-year increase of 10.3% [53]. - Labcorp: Achieved Q4 2025 revenue of $3.52 billion, a year-on-year increase of 5.7% [79]. - Medpace: Reported Q4 2025 revenue of $709 million, a year-on-year increase of 32.1% [88].